Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia
Ee Vien Low, Kalaiarasu M. Peariasamy(Ministry of Health), Wee Ric Kim(Ministry of Health), Mohan Dass Pathmanathan(Ministry of Health), Suresh Kumar Chidambaram(Hospital Sungai Buloh), Zhi Wei Teh(Ministry of Health), Wei Jia Lee(Ministry of Health), Azah Abdul Samad(Management and Science University), Mastura Ismail(Hospital Tuanku Ja’afar), Y Ten(Ministry of Health), Maheshwara Rao Appannan(Ministry of Health)
Cited by 1
Related Papers
Efficacy of telemedicine for the management of cardiovascular disease: a systematic review and meta-analysis
|The Lancet Digital Health|2022|178
Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study
|The Lancet Regional Health - Western Pacific|2020|132
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
|JAMA Internal Medicine|2022|105
Influence of Population Density for COVID-19 Spread in Malaysia: An Ecological Study
|International Journal of Environmental Research and Public Health|2021|85
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
|International Journal of Infectious Diseases|2022|79